Buy MLTX by Mar 4, 2026.

MoonLake ($MLTX) is soaring today, and I believe we are just getting started. This is the beginning of a move from additional data that can drop any day now, and a run-up to an FDA meeting on Dec 15th. Thesis (TL;DR): MoonLake fell off a cliff after its big HS Phase 3 readout—down nearly 90%—because the market hyper-focused on a single narrowly missed endpoint, not the whole data set. Under the surface, sonelokimab (SLK) hit consistent, significant efficacy and is …